Lumefantrine-neusilin® based amorphous multicomponent solid dispersion: In vivo and in vitro characterization
Résumé
Purpose: To develop Neusilin-based amorphous multi-component solid dispersions (NAM-SDs) to improve poor aqueous solubility, low bioavailability and absorption of lumefantrine and enhance the antiplasmodial activity.Methods: Solvent evaporation technique was adopted to produce second-generation SDs (N1 - N3); third-generation SDs (N4 - N6 and N10 - N12); and multi-component SDs, NAM-SDs, (N7 - N9 and N13 - N18). In vitro drug release, in vivo anti-plasmodial activity, differential scanning calorimetry (DSC), and wide-angle x-ray diffraction (WAXD) were carried out on the SDs.Results: The highest drug release (80 %) was observed in multi-component SDs (NAM-SDs, formulation N17 containing Kollidon® VA 64). A significant antiplasmodial activity (p < 0.05) was observed in mice that received NAM-SDs. The DSC and WAXD studies showed that the formulations solubilized and exhibited an amorphous state.Conclusion: Multi-component amorphous-based lumefantrine SDs (NAM-SDs) may serve as a potential alternative carrier system for oral lumefantrine delivery.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 28/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →